The Massachusetts Center for Advanced Biological Innovation and Manufacturing is planning to create a 40,000-sf facility in Watertown, Mass. Supported by $76 million in funding for construction and operations, the project will accelerate the availability of novel therapeutics by collocating research, development, manufacturing, and commercialization activities in the same structure. Featuring eight GMP cleanrooms configured to allow production of both cell and viral vector materials, the center will include labs, offices, and quality control suites. Cross-industry interaction venues will enable academic, medical, and biopharmaceutical partners to collaboratively discover new cell and gene therapies, immunotherapy treatments, and gene editing technologies. The facility will also accommodate training programs in biopharmaceutical manufacturing to build a talent pipeline for skilled workers. Occupancy is expected in early 2022.
The Massachusetts Center for Advanced Biological Innovation is a public-private partnership led by Harvard University and Massachusetts Institute of Technology. Other founding members include Cytiva, Fujifilm Diosynth Biotechnologies, and Alexandria Real Estate Equities, which owns and operates the site where the center will be located.